Ability Pharmaceuticals, SL 

AbilityPharma is a late stage investment opportunity, a company developing clinically (Phase 2) an oral targeted anti-cancer drug


Cancer therapeutics


Development, market readiness, clinical trial



ABTL0812 is a breakthrough cancer drug causing cytotoxic autophagy in cancer cells via ER Stress and Akt/mTOR inhibition

ABTL0812 is oral, highly safe, with single agent efficacy + synergy with chemo/immunotherapy without adding toxicity

Better efficacy endometrial and lung cancer in a phase 2a trial (Spain, France) vs. chemotherapy alone in first-line

This information is confidential, do not share or copy.

Under evaluation at least till: 22nd July

If you want to have more information or you want to review the project, you have to login or register


©2023 BioExpert Network

About cookies

This website uses cookies to give you the best user experience. If you continue browsing you are giving your consent for the acceptance of those cookies and the acceptance of our cookies policy.

If you continue to browse and use this website you are agreeing to comply with and be bound by the following Terms of Use

Aviso de cookies

Log in with your credentials


Forgot your details?

Create Account

Skip to toolbar